Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ISRG vs SYK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ISRG Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

ISRG Overall Winner 6-Pillar Tally: ISRG 4 – 2 SYK Matrix Metrics: ISRG 7 – 3 SYK

As of Nov 16, 2026, Intuitive Surgical Inc. (ISRG) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ISRG carries a Unified Composite Score of 43.4/100 (HOLD) at $439.50 (35.6x Forward P/E, 31.7% operating margin), whereas SYK carries 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin).

  • Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. ISRG 43.4/100 HOLD), ISRG captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (31.7% vs. 24.0% operating margin) and revenue trajectory (+21.7% vs. +7.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ISRG vs SYK
ISRG NASDAQ Head-to-Head Winner
Intuitive Surgical Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$439.50
-0.92% 1D
Market Cap $152.5B
TTM Revenue $11.6B
Forward P/E 35.6x
Beta / 30D Vol 0.82β · 45% Vol
Unified Composite Score
43.4 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 57.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 51
RSI-14: 51.2 · SMA20: $447.57 · SMA50: $419.10
SYK NYSE
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40

6-Pillar Scorecard Institutional Category Breakdown (ISRG 4 – 2 SYK)

Columns: Metric · ISRG · SYK
1. Valuation Multiples SYK
Forward P/E 35.6x 19.0x
Trailing P/E 53.2x 33.3x
PEG Ratio 2.02x 1.54x
EV / Revenue 13.2x 5.0x
2. Growth & Scale ISRG
Revenue Growth (YoY) +21.7% +7.6%
Earnings Growth (YoY) -23.6% -11.7%
TTM Revenue (USD) $11.6B $26.3B
Market Cap $152.5B $118.9B
3. Profitability & Quality ISRG
Gross Margin 66.6% 65.7%
Operating Margin 31.7% 24.0%
Net Profit Margin 25.5% 13.8%
Return on Equity (ROE) 17.9% 16.0%
4. Balance Sheet & Cash Flow ISRG
Cash Generation (TTM) $3.60B $4.57B
Cash Flow Margin 31.1% 17.4%
Net Cash / Leverage $46.12 Book/Sh · 17.9% ROE $11.7B Net Debt (0.64x D/E)
Dividend Yield None (0.00%) 1.10%
5. Options & Positioning SYK
Options Structure Phase SURGE SURGE
Current IV / %ile 31.8% (16th %ile) 28.1% (5th %ile)
Put/Call OI Skew 0.66x (Call-Skewed) 0.30x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat ISRG
OpEx & R&D Intensity 34.9% of Rev ($4.04B) 41.7% of Rev ($11.0B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Concentrated Oligopoly Moat
Supply-Chain Role Medical Instruments & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ISRG (7) vs SYK (3)
Institutional Metric ISRG SYK Criterion Row Edge
Market Capitalization
Scale
$152.5B $118.9B Larger Scale ISRG
Trailing P/E Ratio
Valuation
53.2x 33.3x Lower Multiple SYK
Forward P/E Ratio
Valuation
35.6x 19.0x Lower Multiple SYK
Revenue Growth (YoY)
Growth
+21.7% +7.6% Higher Growth ISRG
Operating Margin (TTM)
Profitability
31.7% 24.0% Higher Margin ISRG
Net Profit Margin
Profitability
25.5% 13.8% Higher Margin ISRG
Return on Equity (ROE)
Capital Efficiency
17.9% 16.0% Higher ROE ISRG
52-Week Range Position
Momentum
40% ($329–$604) 36% ($267–$389) Stronger Trend ISRG
Beta / 30D Volatility
Risk Regime
0.82β · 45% Vol 0.22β · 50% Vol Lower Realized Risk ISRG
Unified Institutional Score
Composite Signal
43.4 / 100 (HOLD) 46.5 / 100 (HOLD) Higher Composite SYK
Trailing 12M Revenue (USD)
Operating Scale
$11.6B $26.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
66.6% 65.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.02x PEG · 13.2x EV/Rev 1.54x PEG · 5.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.60B ($46.12 Book/Sh · 17.9% ROE) $4.57B ($11.7B Net Debt (0.64x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYK +2.47 pp
ISRG: +3.0% · SYK: +5.47%
3M Horizon ISRG +18.56 pp
ISRG: +12.35% · SYK: -6.21%
6M Horizon ISRG +0.68 pp
ISRG: -0.1% · SYK: -0.78%
1Y Horizon SYK +5.51 pp
ISRG: -22.28% · SYK: -16.77%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ISRG Revenue SYK Revenue ISRG Op. Margin SYK Op. Margin Margin Leader
FY2018 $3.72B $13.6B 32.2% 18.7% ISRG
FY2019 $4.48B $14.9B 30.7% 18.2% ISRG
FY2020 $4.36B $14.3B 24.1% 15.5% ISRG
FY2021 $5.71B $17.1B 31.9% 15.1% ISRG
FY2022 $6.22B $18.4B 25.3% 15.4% ISRG
FY2023 $7.12B $20.5B 24.8% 19.0% ISRG
FY2024 $8.35B $22.6B 28.1% 16.3% ISRG
FY2025 $10.1B $25.1B 29.3% 19.5% ISRG

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ISRG SURGE
8d in phase · OBV DISTRIBUTION
Current IV 31.8%
IV Percentile 16th %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ISRG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ISRG Moat Profile High-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $152.5B market capitalization and 31.7% operating margin.
OpEx & R&D Reinvestment 34.9% of Rev ($4.04B)
90D Engineering Disclosures 0 Published · Robot Manipulation
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics

Investor FAQ ISRG vs SYK Key Questions & Quantitative Answers

As of Nov 16, 2026, Intuitive Surgical Inc. (ISRG) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ISRG carries a Unified Composite Score of 43.4/100 (HOLD) at $439.50 (35.6x Forward P/E, 31.7% operating margin), whereas SYK carries 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin). Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. ISRG 43.4/100 HOLD), ISRG captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (31.7% vs. 24.0% operating margin) and revenue trajectory (+21.7% vs. +7.6% YoY).

ISRG leads the Growth & Scale pillar: ISRG posts +21.7% YoY revenue growth and -23.6% YoY earnings growth on $11.6B TTM revenue (66.6% gross margin, 31.7% operating margin), compared with SYK at +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ISRG cumulative revenue shifted +170.4% while SYK shifted +84.7%. In operating R&D and SG&A reinvestment, ISRG deploys 34.9% of Rev ($4.04B) (0 90-day corporate R&D disclosures) versus 41.7% of Rev ($11.0B) (0 disclosures) for SYK.

SYK screens cheaper on headline valuation multiples. ISRG trades at 35.6x Forward P/E, 53.2x Trailing P/E, 2.02x PEG, and 13.2x EV/Revenue (31.1% FCF margin), whereas SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ISRG (17.9% ROE) versus SYK (16.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ISRG carries 31.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.82β · 45% Vol realized risk). By comparison, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.